Mark Schwartz
3 Papers
1 Citations
Mark Schwartz is an academic researcher. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Paul M. Barr,Thomas P. Miller,Jonathan W. Friedberg,Derick R. Peterson,Andrea Baran,Megan M. Herr,Catherine M. Spier,Haiyan Cui,Denise J. Roe,Daniel O. Persky,Carla Casulo,Jamie Littleton,Mark Schwartz,Soham D. Puvvada,Terry H. Landowski,Lisa M. Rimsza,Robert T. Dorr,Richard I. Fisher,Steven H. Bernstein,Margaret M. Briehl +19 more
TL;DR: A phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), finding pretreatment markers of oxidative stress may identify patients likely to respond to this therapeutic approach.
35
A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma.
Sarah T. Wilkinson,Roshanak Bob,Harald Stein,Mark Schwartz,Rita M. Braziel,Randy D. Gascoyne,Lisa M. Rimsza +6 more
TL;DR: This study questioned whether DLBCL cases that have low MHCII expression have a similar gene expression pattern to PBL, and confirmed the hypothesis that M HCII(-)DLBCL have a more plasma cell-like expression pattern than MHC II(+) DLBCl.
1
Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
Lisa M. Rimsza,George E. Wright,Mark Schwartz,Wing C. Chan,Elaine S. Jaffe,Randy D. Gascoyne,Elias Campo,Andreas Rosenwald,German Ott,James R. Cook,Raymond R. Tubbs,Rita M. Braziel,Jan Delabie,Thomas P. Miller,Louis M. Staudt +14 more
TL;DR: This study investigated whether the qNPA technique could be used for accurate classification of COO by using formalin-fixed, paraffin-embedded (FFPE) tissues and found it to be applicable to FFPE tissues with no technical failures, and has potential for significant impact on DLBCL research and clinical trial development.